A Phase 3 interventional study of levetiracetam (LEV) in Epilepsy, Partial, sponsored by UCB Pharma. Completed at 85 sites in 16 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2013-02-12.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 6th largest by enrollment, is one of 5 that started in 2004, is one of 10 in phase 3, and was the 3rd registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 1 Month to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 173 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 7th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2004, is one of 11 in phase 3, and was the 3rd registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying cognition and behavior in children, and continue collection of safety/efficacy data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: levetiracetam (LEV)
Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
Also known as: Keppra
Percentage Change (Reduction) of Partial (Type I) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Percentage Change (Reduction) of Total (Type I, II, III) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period.
Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period.
Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Change (Reduction) From Baseline in Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Change (Reduction) From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Partial Seizure (Type I) Responder Rate (Percent) During the Up-titration/Conversion Phase and by Visit During the Maintenance Phase
The responder rate is defined as the number of responders. A responder is a patient with a 50% or greater change (reduction) in partial seizure frequency per week. Note: Rates were reported as percentages.
Time frame: Up-titration (4 weeks); Maintenance Visits 3-4 (weeks 4-14, 6-15, or 8-16); Visits 4-5 (weeks 14-24, 15-24, or 16-24); Visits 5-6 (weeks 24-36); Visits 6-7 (weeks 36-48)
Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
Time frame: Subjects with up to 24 weeks of exposure
Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
Time frame: Subjects with greater than 24 weeks of exposure
Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
Time frame: Subjects with up to 24 weeks of exposure
Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
Time frame: Subjects with greater than 24 weeks of exposure
Total Seizure (Type I, II, III) Continuously Seizure Free During the Maintenance Period
The measure description is the product limit adjusted percent of subjects seizure free starting from the beginning of the Maintenance Period. The up-titration period is the up to 6 week period of increasing dose prior to the Maintenance Period. The Maintenance Period is the period of stable dosing, subsquent to the up-titration period, which could last from 42 to 48 weeks.
Time frame: greater than or equal to 24 weeks, greater than or equal to 40 weeks
Percent of Subjects With Each Seizure Type During the Evaluation Period
Type I Seizure is a partial onset Seizure (see International League Against Epilepsy definitions). Type II Seizure is a Generalized Seizure (see International League Against Epilepsy definitions). Type III Seizure is a Unknown Seizure Type (see International League Against Epilepsy definitions). A subject could experience more than one seizure type.
Time frame: Evaluation period (48 weeks)
Investigator Global Evaluation Scale
There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).
Time frame: End of Evaluation period (week 48 or at point of early discontinuation)
Parent/Guardian Global Evaluation Scale
There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).
Time frame: End of Evaluation period (week 48 or at point of early discontinuation)
Subject (>=8 Years Old) Global Evaluation Scale
There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).
Time frame: End of Evaluation period (week 48 or at point of early discontinuation)
Leiter-R Associated Memory (AM) Memory Screen Composite Score Change From Baseline to Visit 5 (Week 24) and Visit 7 (Week 48) (4 to 16 Year Olds)
The Leiter-R AM battery has 10 subtests. The raw scores of the subtests are converted into scaled scores. Six composite scores are constructed from the 10 subtest scaled scores. The Memory Screen is one of them. It is composed of 2 subtests the Associated Pairs and Forward Memory. The sum of the Associated Pairs and Forward Memory subtest scaled scores are converted into a Memory composite score normally distributed with a mean and standard deviation of 100 (±15). Higher scores and positive changes from baseline are better. The range of the Memory Screen composite score is 44 to 155.
Time frame: Baseline to Visit 5 (Week 24) and Visit 7 (Week 48)
Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Olds)
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
Time frame: Visit 5 (Week 24)
Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Olds)
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
Time frame: Visit 7 (week 48)
Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Old)
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
Time frame: Visit 5 (week 24)
Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Old)
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
Time frame: Visit 7 (week 48)
102 sites in 17 countries participated in the study, of which 85 sites in 16 countries enrolled subjects in the study. First subject enrolled: 23 October 2004, Last subject last visit: 24 June 2008
| Milestone | Levetiracetam |
|---|---|
| Started | 255 |
| Completed | 180 |
| Not completed | 75 |
| Withdrew: Adverse event | 18 |
| Withdrew: Lack and loss of efficacy | 30 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Other: mother refused to cooperate | 1 |
| Withdrew: Other: given commercial drug in error | 2 |
| Withdrew: Other: parents withdrew consent | 2 |
| Withdrew: Other: non-compliance | 2 |
| Withdrew: Other: primary care physician's decision | 1 |
| Withdrew: Other: moved out of state | 1 |
| Withdrew: Other: underwent surgery for epilepsy | 1 |
| Withdrew: Other: sz worsening, seeking 2nd opinion | 1 |
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
| percent reduction in seizures Per Week | Levetiracetam |
|---|---|
| Up-titration/Conversion | 51.06 (-10.70 to 91.59) |
| Maintenance | 68.87 (-3.60 to 96.61) |
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
| Percent Reduction in Seizures per Week | Levetiracetam |
|---|---|
| Up-titration/Conversion Period | 47.44 (-21.18 to 88.70) |
| Maintenance Period | 66.02 (-3.98 to 95.00) |
| Seizures Per Week | Levetiracetam |
|---|---|
| Up-titration/Conversion Period | 2.85 (0.23 to 26.30) |
| Maintenance Period | 1.49 (0.07 to 17.89) |
| Seizures Per Week | Levetiracetam |
|---|---|
| Up-titration/Conversion Period | 3.15 (0.25 to 31.17) |
| Maintenance Period | 1.91 (0.09 to 24.86) |
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
| Seizures Per Week | Levetiracetam |
|---|---|
| Up-titration/Conversion Period | 0.72 (-0.81 to 7.14) |
| Maintenance Period | 0.93 (-0.33 to 8.99) |
Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.
| Seizures Per Week | Levetiracetam |
|---|---|
| Up-titration/Conversion Period | 0.69 (-0.89 to 7.84) |
| Maintenance Period | 0.93 (-0.33 to 10.70) |
The responder rate is defined as the number of responders. A responder is a patient with a 50% or greater change (reduction) in partial seizure frequency per week. Note: Rates were reported as percentages.
| Percentage of Participants | Levetiracetam |
|---|---|
| Up-titration/Conversion (4 weeks) | 50.6 |
| Maintenance Visits 3-4 (weeks 4-14, 6-15, or 8-16) | 59.8 |
| Maint. Visits 4-5 (weeks 14-24, 15-24, or 16-24); | 65.5 |
| Maintenance Visits 5-6 (weeks 24-36) | 68.2 |
| Maintenance Visits 6-7 (weeks 36-48) | 71.8 |
For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
| Percentage of Days | Levetiracetam |
|---|---|
| Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More) | 0.00 (0.00 to 0.00) |
For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
| Percentage of days | Levetiracetam |
|---|---|
| Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More) | 61.49 (0.00 to 94.07) |
For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
| Percentage of Days | Levetiracetam |
|---|---|
| Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More) | 0.00 (0.00 to 0.00) |
For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.
| Percentage of Days | Levetiracetam |
|---|---|
| Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More) | 58.41 (0.00 to 93.81) |
The measure description is the product limit adjusted percent of subjects seizure free starting from the beginning of the Maintenance Period. The up-titration period is the up to 6 week period of increasing dose prior to the Maintenance Period. The Maintenance Period is the period of stable dosing, subsquent to the up-titration period, which could last from 42 to 48 weeks.
| Percentage of Participants | Levetiracetam |
|---|---|
| >= 24 Weeks | 16.5 |
| >= 40 Weeks | 14.7 |
Type I Seizure is a partial onset Seizure (see International League Against Epilepsy definitions). Type II Seizure is a Generalized Seizure (see International League Against Epilepsy definitions). Type III Seizure is a Unknown Seizure Type (see International League Against Epilepsy definitions). A subject could experience more than one seizure type.
| Percentage of Participants | Levetiracetam |
|---|---|
| Type I | 88.6 |
| Type II | 12.9 |
| Type III | 7.1 |
There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).
| Percentage of Participants | Levetiracetam |
|---|---|
| Improved | 76.1 |
| No Change | 15.3 |
| Worsened | 8.6 |
There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).
| Percentage of Participants | Levetiracetam |
|---|---|
| Improved | 75.7 |
| No Change | 12.6 |
| Worsened | 11.7 |
There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).
| Percentage of Participants | Levetiracetam |
|---|---|
| Improved | 78.9 |
| No Change | 15.5 |
| Worsened | 5.6 |
The Leiter-R AM battery has 10 subtests. The raw scores of the subtests are converted into scaled scores. Six composite scores are constructed from the 10 subtest scaled scores. The Memory Screen is one of them. It is composed of 2 subtests the Associated Pairs and Forward Memory. The sum of the Associated Pairs and Forward Memory subtest scaled scores are converted into a Memory composite score normally distributed with a mean and standard deviation of 100 (±15). Higher scores and positive changes from baseline are better. The range of the Memory Screen composite score is 44 to 155.
| Score on a scale | Levetiracetam |
|---|---|
| Visit 5 (week 24) | 4.8 ± 12.6 |
| Visit 7 (week 48) | 4.5 ± 15.3 |
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
| Number of subjects | Levetiracetam |
|---|---|
| Worsened | 5 |
| Stable | 21 |
| Improved | 4 |
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
| Number of subjects | Levetiracetam |
|---|---|
| Worsened | 7 |
| Stable | 17 |
| Improved | 1 |
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
| Number of subjects | Levetiracetam |
|---|---|
| Worsened | 1 |
| Stable | 20 |
| Improved | 8 |
This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.
| Number of subjects | Levetiracetam |
|---|---|
| Worsened | 1 |
| Stable | 15 |
| Improved | 8 |
Collected over Up to 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam | — | 46/255 (18%) | 206/255 (80.8%) |
| Event | Levetiracetam |
|---|---|
| ConvulsionNervous system disorders | 18/255 |
| PneumoniaInfections and infestations | 6/255 |
| Status epilepticusNervous system disorders | 6/255 |
| Viral infectionInfections and infestations | 5/255 |
| PyrexiaGeneral disorders | 4/255 |
| Upper respiratory tract infectionInfections and infestations | 2/255 |
| Head injuryInjury, poisoning and procedural complications | 2/255 |
| Brain oedemaNervous system disorders | 2/255 |
| AspirationRespiratory, thoracic and mediastinal disorders | 2/255 |
| Obstructive airways disorderRespiratory, thoracic and mediastinal disorders | 2/255 |
| Event | Levetiracetam |
|---|---|
| PyrexiaGeneral disorders | 81/255 |
| Upper respiratory tract infectionInfections and infestations | 62/255 |
| VomitingGastrointestinal disorders | 41/255 |
| NasopharyngitisInfections and infestations | 38/255 |
| DiarrhoeaGastrointestinal disorders | 34/255 |
| HeadacheNervous system disorders | 31/255 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/255 |
| IrritabilityGeneral disorders | 27/255 |
| RashSkin and subcutaneous tissue disorders | 24/255 |
| Otitis mediaInfections and infestations | 21/255 |
| Age, Categorical(Participants) | Levetiracetam |
|---|---|
| <=18 years | 255 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age Continuous(years) | Levetiracetam |
|---|---|
| Mean | 5.28 ± 4.69 |
| Sex: Female, Male(Participants) | Levetiracetam |
|---|---|
| Female | 116 |
| Male | 139 |
| Region of Enrollment(participants) | Levetiracetam |
|---|---|
| United States | 123 |
| Russian Federation | 7 |
| Italy | 6 |
| United Kingdom | 2 |
| India | 20 |
| France | 7 |
| Czech Republic | 9 |
| Hungary | 4 |
| Mexico | 6 |
| Canada | 11 |
| Poland | 2 |
| Brazil | 29 |
| Belgium | 4 |
| Romania | 7 |
| South Africa | 7 |
| Germany | 11 |
The record gives a start of Oct 2004, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam